Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:~  * Ductal carcinoma in situ~ * Stage I-III invasive breast cancer~* At least 3 months since completion of all intended local and systemic therapy, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy, and/or endocrine therapy~  * May have declined recommended treatment provided all treatment intended/agreed upon by the patient and treating physician was completed ≥ 3 months ago~* At least 1 healthy intact breast~  * No prior radiotherapy or mastectomy~ * Prior biopsies allowed~* Any hormone-receptor status~PATIENT CHARACTERISTICS:~* Female~* Pre- or post-menopausal~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective nonhormonal contraception~* No active liver disease~* AST and ALT ≤ 3 times upper limit of normal~* Creatinine clearance ≥ 30 mL/min~* No prior hypersensitivity to any 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor or any of its components~* No other concurrent infectious, inflammatory, or autoimmune diseases (at the discretion of principal investigator)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No daily alcohol use \> 3 standard drinks per day~  * Standard drink defined as 10 grams of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor~* No selective estrogen receptor modulator or aromatase inhibitor within the past 3 months~* No hormone replacement therapy (HRT) within the past 3 months~* No prior estrogen and/or progesterone HRT ≥ 5 years in duration~  * Vaginal estrogen preparations allowed~* No concurrent HRT~* No other cholesterol-lowering drug, including a statin, within the past 3 months~* No concurrent itraconazole, ketoconazole, nefazodone, cyclosporine, HIV protease inhibitors, clarithromycin, erythromycin, mibefradil, carbamazepine, bosentan, chaparral, amiodarone, or verapamil~* No concurrent daily grapefruit juice consumption \> 8 ounces per day~* No other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): Simvastatin 40 mg for 24-28 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).